Previous 10 | Next 10 |
2023-09-26 17:13:07 ET More on Immunovant Seeking Alpha’s Quant Rating on Immunovant Historical earnings data for Immunovant Financial information for Immunovant Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrade) Immunovant...
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the commencement of a proposed underwritten public offering and concurrent private placement of...
2023-09-26 15:23:00 ET Shares of Immunovant (NASDAQ: IMVT) were up more than 96% as of 3 p.m. on Tuesday. The clinical-stage immunology company, a unit of Roivant Sciences , announced positive trial information on an autoimmune disorder therapy. Roivant's shares were up more t...
2023-09-26 14:17:50 ET More on Argenx, OmniAb, etc. OmniAb: Hold For Growth argenx: Three Important Milestones Reached In 2023, More To Come argenx: CIDP Data Better Than Expected, Maintaining Hold Rating argenx: Hytrulo Finally Approved, But CIDP Is A Bigger...
2023-09-26 13:46:32 ET Gainers: Soleno Therapeutics ( SLNO ) +446% . Femasys ( FEMY ) +271% . Immunovant ( IMVT ) +101% . Intercept Pharmaceuticals ( ICPT ) +79% . Acasti Pharma ( ACST ) +35% . Applied Therapeutics ( APLT ...
2023-09-26 12:15:20 ET DENVER, Colo., Sept 26, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Soleno Therapeutics (NASDAQ: SLNO), Femasys (NASDAQ: FEMY), Immunovant (NASDAQ: IMVT), Bullfrog AI (NA...
2023-09-26 11:10:50 ET Summary Immunovant's IMVT-1402 shows early promise with dose-dependent IgG reduction and a decent safety profile, rejuvenating the company's drug pipeline. Despite a solid 20.9-month cash runway, escalating R&D expenses and liquidity concerns necessitate...
Shares of Immunovant, Inc. (NASDAQ: IMVT) traded at a new 52-week high today and are currently trading at $34.98. So far today, approximately 13.09M shares have been exchanged, as compared to an average 30-day volume of 1.11M shares. Immunovant, Inc., a clinical-stage biopharmaceutical compan...
2023-09-26 10:00:07 ET DENVER, Colo., Sept 26, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Soleno Therapeutics (NASDAQ: SLNO), Femasys (NASDAQ: FEMY), Immunovant (NASDAQ: IMVT), Bullfrog AI (NASDAQ: B...
2023-09-26 09:10:25 ET Investors seem to have lost their conviction in the stock market lately, as even brief attempts to rebound from declines have met with stiff resistance. For instance, Monday's trading session gave market participants some optimism about how the economy could weather d...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 13:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ending March 31, 2025 Topline data from the bato...